Voyager Therapeutics wins FDA IND clearance for VY1706, plans early Alzheimer’s trial start in H2 2026

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

VYGR

0.00
  • Voyager Therapeutics won FDA IND clearance for VY1706, setting up a first-in-human study in adults with early Alzheimer’s disease.
  • Dosing is expected to start in the second half of 2026, marking a key clinical inflection point for the tau-targeted gene therapy program.
  • Preclinical toxicology work in non-human primates supported the trial start, showing a tolerability profile management characterized as favorable.
  • Additional preclinical findings on VY1706 are scheduled for presentation at AAIC 2026 in London on July 13, 2026.
  • No clinical efficacy results have been reported yet; the next catalyst is initial human dosing later this year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.